Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers

Transfusion
Peter SchlenkeJean-Pierre Cazenave

Abstract

A photochemical treatment (PCT) process has been developed to inactivate pathogens and white blood cells (WBCs) in therapeutic plasma. Process validation studies were performed in three European blood centers under routine operating conditions. Each center prepared 30 apheresis and 30 to 36 whole blood-derived plasma units for PCT. Each whole blood-derived plasma unit contained a mixture of two to three matched donations. After removal of pretreatment control samples (control fresh-frozen plasma [C-FFP]), 546 to 635 mL of plasma was treated with 15 mL of 6 mmol per L amotosalen, 3 J per cm(2) UVA treatment, and removal of residual amotosalen with a compound adsorption device. After processing, plasma samples (PCT-FFP) were withdrawn, frozen at -60 degrees C within 8 hours of collection, and assayed for coagulation factors and residual amotosalen. A total of 186 units of plasma were processed. The mean prothrombin time (12.2 +/- 0.6 sec) and activated partial thromboplastin time (32.1 +/- 3.2 sec) of PCT-FFP were slightly prolonged compared to C-FFP. Fibrinogen and Factor (F)VIII were most sensitive to PCT (26% mean reduction). PCT-FFP, however, retained sufficient levels of fibrinogen (217 +/- 43 mg/dL) and FVIII (97 +/- 29 IU/...Continue Reading

References

Nov 17, 2007·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Katharina PockJürgen Römisch

❮ Previous
Next ❯

Citations

Nov 8, 2011·Photochemistry and Photobiology·Jose-Luis SagripantiHans-Jürgen Marschall
Jul 23, 2011·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Johannes Irsch, Lily Lin
Jul 2, 2011·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·G CanelliniJ-D Tissot
Oct 12, 2010·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·S Gerald Sandler
Jan 19, 2010·Biologicals : Journal of the International Association of Biological Standardization·Chantal Fournier-Wirth, Joliette Coste
Oct 2, 2009·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·John McClaskeyChristopher A Tormey
Sep 29, 2009·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Luis LarreaRoberto Roig
Mar 24, 2009·Transfusion Medicine Reviews·Christopher Prowse
Aug 20, 2008·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Joan CidRamon Pau Pla
Apr 28, 2009·Transfusion·Harvey G KleinUNKNOWN NHLBI Working Group on Research Opportunities for the Pathogen Reduction/Inactivation of Blood Components
Apr 1, 2015·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Johannes Irsch, Jerard Seghatchian
May 23, 2014·Journal of Thrombosis and Thrombolysis·Giancarlo Maria Liumbruno, Massimo Franchini
Apr 27, 2016·Hematology/oncology Clinics of North America·Alan Tinmouth

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.